Stocksigma LogoStocksigma Logo

Glenmark Pharma expects strong H2 recovery driven by operating leverage and US growth

Glenmark Pharma expects H2 FY27 to be significantly stronger than H1, driven by operating leverage following investments in field force and oncology

Glenmark Eyes Strong H2 Recovery: CFO Anurag Mantri Explains What's Ahead

NDTV Profit · 13 Nov 2026 · 13 min

Management interview of Glenmark Pharmaceuticals Ltd (GLENMARK), with 6 key numbers discussed.

Glenmark Pharma expects H2 FY27 to be significantly stronger than H1, driven by operating leverage following investments in field force and oncology. The company expects its core EBITDA margin to recover, maintaining its 21-22% target for FY27. North America revenue is guided to grow 25-30% this year, supported by Ryaltris in-house commercialisation and upcoming Monroe facility launches from FY28. Global sales for Ryaltris are projected to surpass USD 130mn in FY27 and exceed USD 300mn over the next three to four years.

Watch the interview on YouTube